I.

Baseline characteristics of patients before starting treatment

1. Baseline clinical data of patients
Treatment Treatment Test of Sig. crude Adjuste CI
naive experienced (p-value) d OD 95%
Age in years
(Mean ±SD)
Gender: n (%)
‒ Male
‒ Female
BMI: n (%)
‒ Underweight
‒ Normal
‒ Overweight
‒ Obese
‒ Extremely obese
Child Class: n (%)
‒ Class A
‒ Class B
‒ Class C
Arrhythmia by
ECG: n (%)
‒ Negative
‒ positive
Liver by US: n (%)
‒ No cirrhosis
‒ Cirrhosis
Spleen by US: n (%)
‒ Normal
‒ Large
Ascites by US: n (%)
‒ None 100 %
‒ Mild/moderate
‒ Severe
HCC by US: n (%)
‒ Negative 100 %
‒ Positive
Esophageal varices
by UGITE: n (%)
‒ None
‒ Grade 1
‒ Grade 2
‒ Grade 3/4 0%
BMI: body mass index, ECG: Electrocardiography, US: ultrasound, HCC: hepatocellular carcinoma,
UGITE: Upper Gastro-intestinal Tract Endoscopy
 2. Baseline laboratory and viral load data of patients:
Treatmen Treatme Test of crude Adjust CI
t naive nt Sig. (p- ed OD 95%
experienc value)
ed
Hemoglobin (g/dL)
WBC (x103
cells/mm3)
ANC (x103 cells/mm3)
Platelets (x103
cells/mm3)
INR
ALT (IU/L)
AST (IU/L)
Albumin (g/dL)
Bilirubin (mg/dL)
AFP (IU/L)
Urea (mg/dL)
Creatinine (mg/dL)
Creatinine clearance
(mL/min)
HCV-RNA Log10
(IU/mL)
Data are expressed as mean ± standard deviation, WBC: White blood cells, ANC:
Absolute neutrophilic count, INR: international normalized ratio, ALT: alanine
transaminase, AST: aspartate transaminase, AFP: alfa-fetoprotein, HCV: hepatitis C
virus, RNA: ribonucleic acid
 II. Follow-up characteristics of patients after 4 weeks of treatment
1. Clinical data of patients after 4 weeks of treatment
Treatment Treatment Test of Sig. crude Adjuste CI
naive experienced (p-value) d OD 95%
Child Class: n (%)
‒ Class A
‒ Class B
‒ Class C
Arrhythmia by ECG:
n (%)
‒ Negative
‒ positive
Ascites by US: n (%)
‒ None 100 %
‒ Mild/moderate
‒ Severe
HCC by US: n (%)
‒ Negative 100 %
‒ Positive
Esophageal varices by
UGITE: n (%)
‒ None
‒ Grade 1
‒ Grade 2
‒ Grade 3/4 0%
BMI: body mass index, ECG: Electrocardiography, US: ultrasound, HCC: hepatocellular carcinoma,
UGITE: Upper Gastro-intestinal Tract Endoscopy
 2. Laboratory data of patients after 4 weeks of treatment
Treatmen Treatme Test of crude Adjust CI
t naive nt Sig. (p- ed OD 95%
experienc value)
ed
Hemoglobin (g/dL)
WBC (x103
cells/mm3)
ANC (x103 cells/mm3)
Platelets (x103
cells/mm3)
INR
ALT (IU/L)
AST (IU/L)
Albumin (g/dL)
Bilirubin (mg/dL)
AFP (IU/L)
Urea (mg/dL)
Creatinine (mg/dL)
Creatinine clearance
(mL/min)
HCV-RNA Log10 by
PCR (IU/mL)
Data are expressed as mean ± standard deviation, WBC: White blood cells, ANC:
Absolute neutrophilic count, INR: international normalized ratio, ALT: alanine
transaminase, AST: aspartate transaminase, AFP: alfa-fetoprotein, HCV: hepatitis C
virus, RNA: ribonucleic acid
 3. Primary Efficacy and Safety Endpoints after 4 weeks of treatment

Treatment Treatment Test of Sig. crude Adjuste CI

naive experienced (p-value) d OD 95%
HCV-RNA by PCR: n (%)
‒ Negative
‒ Positive
Anemia: n (%)
Arrhythmia: n (%)
Hepatotoxicity: n (%)
HRS: n (%)
HCV: hepatitis C virus, RNA: ribonucleic acid, HRS: Hepatorenal syndrome